Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

LVRS Reimbursement Study On 12-Year Pace Based On Current Enrollment

This article was originally published in The Gray Sheet

Executive Summary

A HCFA/NIH study to gather data on lung volume reduction surgery (LVRS) will take 12 years to complete rather than the projected seven, attorney Michael Gaba, of the law firm of Oppenheimer Wolff Donnelly & Bayh, suggested Dec. 6 at the Medical Device Manufacturers Association's Second Annual Coverage and Reimbursement Conference in Philadelphia, Pennsylvania.

You may also be interested in...



Medicare Copay/Deductible Waivers Apply Only To Emphysema Study - OIG

The HHS Office of Inspector General's conclusion that Medicare copayments and deductibles should be waived for participants in the National Emphysema Treatment Trial (NETT) do not apply to other clinical studies.

Medicare Copay/Deductible Waivers Apply Only To Emphysema Study - OIG

The HHS Office of Inspector General's conclusion that Medicare copayments and deductibles should be waived for participants in the National Emphysema Treatment Trial (NETT) do not apply to other clinical studies.

MCAC Executive Committee Requests Guidance On Cost Effectiveness

The executive steering committee of the Medicare Coverage Advisory Committee is seeking clear instruction from the Health Care Financing Administration on whether cost effectiveness should be considered by the expert panels charged with making coverage recommendations.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT012703

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel